Anhydride U tRNA Modification for Precise RNA Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for detecting and quantifying novel RNA modifications, such as anhydride U, which play a crucial role in tRNA stability and are associated with human diseases, and there is a need for advanced systems and methods to produce and regulate these modifications for therapeutic applications.
Innovation Solution
The discovery and enzymatic synthesis of anhydride U, along with methods for its detection and regulation, including the use of MLC-SEQ and NGMS-Seq platforms, enable the production and quantification of anhydride U in tRNA molecules, and its incorporation into RNA therapies for disease treatment and vaccine formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used for RNA modifications, then existing modifications can be detected, but novel RNA modifications like anhydride U cannot be detected or quantified
Solution Approach 1:
The patent employs advanced mass spectrometry parameters and methodologies (NGMS-Seq, MLC-SEQ) to detect and quantify novel RNA modifications. By changing the detection parameters from conventional to next-generation mass spectrometry, the system achieves both high precision for known modifications and expanded versatility to detect novel modifications like anhydride U at position 19 of tRNA
Solution Approach 2:
The patent performs preliminary enzymatic synthesis of anhydride U using aminocarboxypropyltransferase and S-adenosyl methionine before detection. This preliminary action creates a standardized reference that enables subsequent precise detection and quantification of the novel modification in tRNA samples
2Measurement precision
If advanced detection methods like NGMS-Seq and MLC-SEQ are used, then novel RNA modifications can be detected and quantified, but the device complexity and method complexity increase
Solution Approach 1:
The patent introduces enzymatic intermediaries (aminocarboxypropyltransferase and S-adenosyl methionine) that mediate the formation of anhydride U in a controlled manner before detection. This intermediary step simplifies the overall process by creating a standardized modification that can be detected with high accuracy using advanced but manageable mass spectrometry systems
Solution Approach 2:
The detection process is segmented into distinct phases: enzymatic synthesis of anhydride U, followed by separate detection using NGMS-Seq or MLC-SEQ methods. This segmentation allows each step to be optimized independently, reducing overall system complexity while maintaining high quantification accuracy
3Reliability
If anhydride U is incorporated into RNA therapies, then stability and efficacy are enhanced, but the manufacturing complexity increases
Solution Approach 1:
The patent employs self-service enzymatic synthesis where aminocarboxypropyltransferase automatically catalyzes the formation of anhydride U from uridine and S-adenosyl methionine within the RNA synthesis process. This self-service approach integrates modification directly into manufacturing, enhancing RNA therapy stability while minimizing additional production complexity
Solution Approach 2:
The patent changes the chemical parameter of the RNA molecule by incorporating anhydride U modification at specific positions. This parameter change (adding the anhydride group) enhances RNA stability and efficacy for therapeutic applications, while the enzymatic nature of the modification keeps manufacturing complexity manageable
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the stability and efficacy of RNA-based therapies and vaccines by utilizing anhydride U, providing advanced gene therapy and immune response generation, while enabling precise detection and quantification of RNA modifications for diagnostic and therapeutic purposes.
Implementation Method 1
aminocarboxypropyltransferase is added leading to the production of 3-3-amino-3-carboxypropyfluoride (acp3U)
Implementation Method 2
The structure of the anhydride U is depicted in (FIG. 3A). Further, it is observed that, at position 19 in tsRNACys and tRNACys, acp3U and anhydride U coexist.
Implementation Method 3
nucleotide modifications in this region may provide regional stability or flexibility
Data Source
AI summary
The present disclosure relates to the identification of a novel nucleoside modification, referred to herein as anhydride U, present in tRNA molecules within the cell. The present disclosure further relates to the enzymatic and chemical production of anhydride U as well as methods for detecting and regulating the presence of anhydride U within the cell.